Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-01-24

Clinical Trial Update: A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial evaluating LBR-101 for episodic migraine has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LBR-101

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Episodic Migraine Headache | Phase 2 | Status: COMPLETED | Results posted: 2022-01-24